Assertio (NASDAQ:ASRT) Receives “Buy” Rating from HC Wainwright

Assertio (NASDAQ:ASRT)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 332.25% from the stock’s previous close.

Separately, StockNews.com upgraded shares of Assertio from a “hold” rating to a “buy” rating in a research report on Wednesday, November 13th.

Assertio Trading Down 1.6 %

NASDAQ ASRT opened at $0.93 on Monday. Assertio has a 12 month low of $0.73 and a 12 month high of $1.80. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.01 and a quick ratio of 1.57. The company has a market capitalization of $88.36 million, a price-to-earnings ratio of -1.25 and a beta of 0.82. The company’s fifty day moving average price is $1.00 and its two-hundred day moving average price is $1.17.

Assertio (NASDAQ:ASRT) last posted its quarterly earnings data on Monday, November 11th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02. Assertio had a negative net margin of 54.46% and a positive return on equity of 3.79%. The firm had revenue of $29.20 million for the quarter, compared to the consensus estimate of $29.29 million. During the same period in the prior year, the firm posted ($0.01) EPS. As a group, research analysts predict that Assertio will post -0.15 earnings per share for the current fiscal year.

Insider Transactions at Assertio

In other Assertio news, Director Heather L. Mason purchased 75,000 shares of Assertio stock in a transaction dated Monday, November 18th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $60,000.00. Following the transaction, the director now owns 287,650 shares in the company, valued at $230,120. This represents a 35.27 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.20% of the company’s stock.

Institutional Trading of Assertio

Hedge funds have recently bought and sold shares of the company. Captrust Financial Advisors bought a new stake in Assertio in the 3rd quarter valued at about $26,000. Point72 DIFC Ltd bought a new stake in Assertio in the 2nd quarter valued at about $40,000. Thurston Springer Miller Herd & Titak Inc. lifted its position in Assertio by 304.0% in the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 50,500 shares of the company’s stock valued at $60,000 after purchasing an additional 38,000 shares during the last quarter. Marshall Wace LLP bought a new stake in Assertio in the 2nd quarter valued at about $70,000. Finally, Los Angeles Capital Management LLC bought a new stake in Assertio in the 2nd quarter valued at about $77,000. 48.96% of the stock is currently owned by institutional investors.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.